A High Cytosol Value of Urokinase-Type Plasminogen Activator (uPA) May Be Predictive of Early Relapse in Primary Breast Cancer

References

• Folkman J. What is the evidence that tumors are angiogenic dependent?. J. Natl Cancer Inst. 1990; 82: 4–6
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971; 285: 1182–1186
   PubMed Web of Science ®Google Scholar
• Horak E.R., Leek R., Klenk N., LeJeune S., Smith K., Stuart N., Greenall M., Stepniewska K., Harris A.L. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 1120–1124
   PubMed Web of Science ®Google Scholar
• Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E.N., Moore D.H., Meli S., Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl Cancer Inst. 1992; 84: 1875–1887
   PubMed Web of Science ®Google Scholar
• Van Hoef M.E.H.N., Knox W.F., Dhesi S.S., Howell A., Schor A.M. Assessment of tumor vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur. J. Cancer 1993; 29A: 1141–1145
   PubMed Web of Science ®Google Scholar
• Fox S.B., Turner G.D.H., Leek R.D., Whitehouse R.M., Gatter K.C., Harris A.L. The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecular expression in tumor endothelium. Breast Cancer Res. Treat. 1995; 36: 219–226
   PubMed Web of Science ®Google Scholar
• Goulding H., Nik Abdul Rashid N.F., Robertson J.F., Bell J.A., Elston C.W., Blamey R.W., Ellis I.O. Assessment of angiogenesis in breast carcinoma: an important factor in prognosis?. Hum. Pathol. 1995; 26: 1196–1200
   PubMed Web of Science ®Google Scholar
• Bevilacqua P., Barbareschi M., Verderio P., Boracchi P., Caffo O., Dalla Palma P., Meli S., Weidner N., Gasparini G. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma. Results of a multiparametric study. Breast Cancer Res. Treat. 1995; 36: 205–217
   PubMed Web of Science ®Google Scholar
• Toi M., Inada K., Suzuki H., Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res. Treat. 1995; 36: 193–204
   PubMed Web of Science ®Google Scholar
• Obermair A., Kurz C., Czerwenka K., Thoma M., Kaider A., Wagner T., Gitsch G., Sevelda P. Microvessel density and vessel invasion in lymph-node negative breast cancer: effect on recurrence-free survival. Int. J. Cancer 1995; 62: 126–131
   PubMed Web of Science ®Google Scholar
• Axelsson K., Ljung B.-M.E., More D.H., II, Thor A.D., Chew K.L., Edgerton S.M., Smitrh H.S., Mayall B.H. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J. Natl Cancer Inst. 1995; 87: 997–1008
   PubMed Web of Science ®Google Scholar
• Gasparini G. Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the vicenza studies. Eur. J. Cancer 1993; 32A: 2485–2493
   Google Scholar
• Grøndhal-Hansen J., Christensen I.J., Rosenquist C., Brünner N., Mouridsen H.T., Danø K., Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993; 53: 2513–2521
   PubMed Web of Science ®Google Scholar
• Jänicke F., Schmitt M., Pache L., Ulm K., Harbeck N., Höfler H., Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res. Treat. 1993; 24: 195–208
   PubMed Web of Science ®Google Scholar
• Bouchet C., Spyratos F., Martin P.M., Hacène K., Gentile A., Oglobine J. Prognostic value of urokinase-type plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br. J. Cancer 1994; 69: 398–405
   PubMed Web of Science ®Google Scholar
• Duffy M.J. Proteases as prognostic markers in cancer. Clin. Cancer Res. 1996; 2: 613–618
   PubMed Web of Science ®Google Scholar
• Kondo Y., Arii S., Mori A., Furutani M., Chiba T., Imamura M. Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line. Clin. Cancer Res. 2000; 6: 622–630
   PubMed Web of Science ®Google Scholar
• Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841–844
   PubMed Web of Science ®Google Scholar
• Skobe M., Rockwell P., Goldstein N., Vosseler S., Fusenig N.E. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med. 1997; 3: 1222–1227
   PubMed Web of Science ®Google Scholar
• Gasparini G., Toi M., Gion M., Verderio P., Dittadi R., Hanatani M., Matsubara I., Vinante O., Bonoldi E., Boracchi P., Gatti C., Suzuki H., Tominaga T. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. Natl Cancer Inst. 1997; 89: 139–147
   PubMed Web of Science ®Google Scholar
• Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403–410
   PubMed Web of Science ®Google Scholar
• EORTC Breast Cancer Co-Operative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer: report of the second EORTC workshop, held on 16–17 March, 1979, in The Netherlands Cancer Institute. Eur. J. Cancer 1980; 16: 1513–1515
   PubMed Web of Science ®Google Scholar
• Goldhirsch A., Wood W.C., Senn H.J., Glick J.H., Gelber R.D. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J. Natl Cancer Inst. 1995; 87: 1441–1445
   PubMed Web of Science ®Google Scholar
• Duffy M.J., O'Grady P., Devaney D., O'Siorain L., Fennelly J.J., Lijnen H.J. Urokinase-plasminogen activator, a marker for aggressive breast cancers. Preliminary report. Cancer 1988; 62: 531–533
   PubMed Web of Science ®Google Scholar
• Jänicke F., Schmitt M., Ulm K., Gössner W., Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 1989; 8670: 1049
   Google Scholar
• Jänicke F., Schmitt M., Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Sem. Thromb. Hemostasis 1991; 17: 303–312
   PubMed Web of Science ®Google Scholar
• Foekens J.A., Schmitt M., van Putten W.L.J., Peters H.A., Bontenbal M., Jänicke F., Klijn J.G.M. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 1992; 52: 6101–6105
   PubMed Web of Science ®Google Scholar
• Foekens J.A., Schmitt M., van Putten W.L.J., Peters H.A., Kramer M.D., Jänicke F., Klijn J.G.M. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J. Clin. Oncol. 1994; 12: 1648–1658
   PubMed Web of Science ®Google Scholar
• Grøndhal-Hansen J., Peters H.A., van Putten W.L.J., Look M.P., Pappot H., Rønne E., Danø K., Klijn J.G.M., Brünner N., Foekens J.A. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin. Cancer Res. 1995; 1: 1079–1087
   PubMed Web of Science ®Google Scholar
• Fernö M., Bendahl P.O., Borg Å., Brundell J., Hirschberg L., Olsson H., Killander D. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with illuminometric immunoassays. Eur. J. Cancer 1996; 32: 793–801
   Google Scholar
• Kim S.J., Siba E., Kobayashi T., Yayoi E., Furukawa J., Takatsuka Y., Shin E., Koyama H., Inaji H., Takai S. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type 1 and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin. Cancer Res. 1998; 4: 177–182
   PubMed Web of Science ®Google Scholar
• Knoop A., Andreasen P.A., Andersen J.A., Hansen S., Laenkholm A.V., Simonsen A.C., Andersen J., Overgaard J., Rose C. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor 1 in primary breast cancer. Br. J. Cancer 1998; 77: 932–940
   PubMed Web of Science ®Google Scholar
• Bouchet C., Hacène K., Martin P.M., Becette V., Tubiana-Hulin M., Lasry S., Oglobine J., Spyratos F. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J. Clin. Oncol. 1999; 17: 3048–3057
   PubMed Web of Science ®Google Scholar
• Harbeck N., Thomssen C., Berger U., Ulm K., Kates R.E., Hofler H., Janicke F., Graeff H., Schmitt M. Invasion marker PAI-1 remains a strong prognostic factor after long term follow up both for primary breast cancer and following first relapse. Breast Cancer Res. Treat. 1999; 54: 147–157
   PubMed Web of Science ®Google Scholar
• Foekens J.A., Peters H.A., Look M.P., Portengen H., Schmitt M., Kramer M.D., Brünner N., Jänicke F., Meijer-van Gelder M.E., Henzen-Logmans S.C., van Putten W.L.J., Klijn J.G.M. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000; 60: 636–643
   PubMed Web of Science ®Google Scholar
• Schmitt M., Harbeck N., Thomssen C., Wilhem O., Magdolen V., Reuning U., Ulm K., Höfler H., Jänicke F., Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemostasis 1997; 78: 285–296
   PubMed Web of Science ®Google Scholar
• Reilly D., Christensen L., Duch M., Nolan N., Duffy M.J., Andreasen P.A. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int. J. Cancer 1992; 50: 208–214
   PubMed Web of Science ®Google Scholar
• Pyke C., Kristensen P., Ralfkiær E., Eriksen J., Danø K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res. 1991; 51: 4067–4071
   PubMed Web of Science ®Google Scholar
• Schnaper H.W., McGowan K.A., Kim-Schulze S., Cid M.C. Oestrogen and endothelial cell angiogenic activity. Clin. Exp. Pharmacol. Physiol. 1996; 23: 247–250
   PubMed Web of Science ®Google Scholar
• Senger D.R., Van De Walter L., Brown L.F., Nagy J.A., Yeo K.T., Yeo T.K., Berse B., Jackman R.W., Dvorak A.M., Dvorak H.F. Vascular permeability factor (VPF,VEGF) in tumor biology. Cancer Metastasis Rev. 1993; 12: 303–324
   PubMed Web of Science ®Google Scholar
• Banerjee S.K., Sarkar D.K., Weston A.P., De A., Campbell D.R. Overexpression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis. Carcinogenesis 1997; 18: 1155–1161
   PubMed Web of Science ®Google Scholar
• Prechtl A., Harbeck N., Thomssen C., Meisner C., Braun M., Untch M., Wieland M., Lisboa B., Cufer T., Graeff H., Selbmann K., Schmitt M., Jänicke F. Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer. Int. J. Biol. Marker 2000; 15: 73–78
   PubMed Web of Science ®Google Scholar